A lower serum uric acid (UA) level has been associated with a higher mortality rate in haemodialysis patients. We investigated the long-term confounding factors of UA and mortality, and fitted a marginal structural model (MSM) based on the causal effect of xanthine oxidoreductase inhibitors (XORi). In total, 2429 patients on regular dialysis from April 2013 to March 2016 were included, and divided into quintiles by serum UA with Kaplan Meier (KM) curves and log rank analysis. Baseline characteristics were evaluated for relationships with all-cause mortality and cardiovascular disease (CVD) using the Cox hazard model. The MSM was used to control for time-dependent confounders of the XORi treatment effect. KM curves indicated that patients in the highest UA quintile had better outcomes than those in the lowest UA quintile. UA was not correlated with all-cause mortality or CVD events in the Cox model; however, the hazard ratio (HR) for mortality was 0.96 for the baseline administration of XORi. The MSM analysis for the effect of XORi treatment on all-cause mortality revealed a HR of 0.24 (95% confidence interval: 0.15-0.38) in all cohorts. These results suggest that XORi improved all-cause mortality in endstage renal disease, irrespective of the serum UA level.
Marginal Structural Model Analysis. We utilised a marginal structural model (MSM) for this longitudinal repeated measure analysis to estimate the treatment effect of XORi in haemodialysis patients according to the method of Robins and Hernan 15, 16 (Fig. 4 ). For analysis of the treatment propensity score, the factors strongly influencing treatment choice as determined by logistic analysis are shown in Supplementary Table S2 . Treatment selection was influenced by age, BMI, endocrine metabolic disorders, mental disorders, nervous system disorders, eye/ear complications, diseases of the veins, hypotension, respiratory system and digestive system complications, musculoskeletal and injury at baseline complications, previous XORi, previous UA level, previous albumin, previous normalized protein catabolic rate (nPCR), previous creatinine generation rate (CGR), previous ferritin level, previous serum sodium level and previous dialysis adequacy (KT/V). After establishing the Figure 1 . Study population selection from the Step II data system. We identified maintenance haemodialysis patients who attended our group's clinics from April 2013 to March 2016; 2429 patients were finally included in the study cohort. p Figure S1 , Supplementary Table S3 ), the calculated stabilized weight for treatment was defined as follows. The mean stabilized weight was 1.11, the standard deviation was 0.58 (minimum 0.0089, maximum 21.95), the 95% point was 1.94, and the 99% point was 3.62 ( Supplementary Table S3 ).
The treatment effect of the XOR inhibitors was estimated by MSM utilizing stabilized weight for all-cause mortality was associated with an HR of 0.24 (95% CI 0.15-0.38) in all of the quintiles (Fig. 5a ). The quintile-1 HR was 0.17 (95% CI 0.085-0.32), quintile-2 HR 0.27 (95% CI 0.11-0.67), quintile-3 HR 0.25 (95% CI 0.077-0.82), quintile-4 HR 0.11 (95% CI 0.023-0.56) and quintile-5 HR 0.16 (95% CI 0.037-0.67). The treatment effect of XORi on CVD events was associated with an HR of 0.92 (95% CI 0.76-1.12) in all of the quintiles (Fig. 5b) . Nevertheless, the treatment effect of XORi for hypertensive disease included in the CVD events indicated a significantly preventive effect, with an HR of 0.35 (95% CI 0.16-0.75) ( Fig. 5b ).
Sensitivity analysis was performed via MSM, since a small number of patients with unusual prescription patterns had a large effect on the analysis after multiplying by 36 visits. The stabilized weight was truncated after the 95 th percentile (0.69-1.94) or 99 th percentile (0.26-3.62) ( Supplementary Table S3 ). After truncation at each level, the weights were reset to each point level (e.g., weights <0.26 were reset to 0.26; otherwise, weights >3.62 were reset to 3.62) [15] [16] [17] . The 99 th percentile truncated MSM analysis of HR for all-cause mortality was found to be 0.24 (95% CI 0.152-0.370). The 95 th percentile truncated MSM analysis of HR for all-cause mortality was found to be 0.24 (95% CI 0.161-0.368). The HR for CVD events with 95 th percentile weight analysis was 0.91 (95% CI 0.770-1.065). The HR for new onset hypertensive diseases with 95 th percentile weight analysis was 0.45 (95% CI 0.215-0.939), with a 99 th percentile of 0.40 (95% CI 0.190-0.843).
Discussion
We used observational MSM to estimate HR of 0.24 for all-cause mortality in patients receiving XORi in this 3-year follow up study. Chen et al. 18 reported that patients with gout treated with UA-lowering agents for over 2 years had a lower risk of all-cause mortality (HR 0.39 for allopurinol, 0.24 for benzbromarone) in a matched cohort in Taiwan. The results of an analysis conducted in Taiwan were similar to the results obtained in our study, in which MSM was applied. MSM was used to analyse repeatedly measured data; each visit and each patient was adjusted by using inverse probability of treatment weighted (IPTW) estimates with 2429 cases and 36 visits.
Kaplan Meier curves and log rank analysis showed that the lower quintile of UA exhibited a less favourable outcome than the higher quintile, but Cox hazard analysis showed that the UA level at baseline was not correlated with all-cause mortality or CVD events. Cox hazard analysis also indicated a preventive effect of baseline XORi administration on mortality (HR 0.962, 95% CI 0.926-0.999).
With regards to the other well-known confounders in haemodialysis, only XORi treatment at baseline was correlated with the outcomes. However, if other covariates such as certain well-known confounders (e.g., Alb, Hb, KT/V) were estimated as time dependent, the HR of these covariates would be different from the baseline Cox model. Thus, further investigation with a time dependent model is needed. The HR of 0.962 for XORi administration was estimated only at baseline and would likely change with different treatment patterns as a result of the cumulative treatment effects over the period of 3 years in this time-dependent repeated measured MSM analysis. A lower serum UA level in haemodialysis was correlated with unfavourable outcomes, but was not identified as the main cause of mortality in the Cox model, further suggesting that the therapeutic target might be the underlying high XO status caused by uraemia, hypertension, hypoxia or chronic inflammatory diseases. While Beberashviliet et al. reported an all-cause mortality rate of 43.5% in their dialysis patients 9 , our study showed a death rate of 16.5%. This difference in mortality may be related to the high-quality management of dialysis patients in Japan 19 . Beberashviliet et al. also reported an HR of 0.89 for all-cause mortality with serum uric acid levels in haemodialysis patients in a stepwise method using an adjusted Cox model 11 . However, our result using a fully adjusted Cox model did not show a significant correlation with the outcome. Since UA is rapidly removed from the patients during each dialysis session, serum UA level itself should not be considered as an appropriate hyperuricaemia marker in haemodialysis CKD patient. Alternatively, from the results in the present study, it may be recommended that dialysis patients be treated with XORi to prevent 21 .
In contrast to the results obtained in a dialysis patient population, those obtained in a healthy normotensive population showed that higher UA levels were related to unfavourable outcomes in large-cohort observational studies 22, 23 . However, considering the antioxidative effect of UA, a low UA level may even be unfavourable 24 . Since UA reportedly reduces oxidative stress and is suggested to prolong life span 24 , it appears that lowering the serum UA may paradoxically reduce the beneficial antioxidative effect of UA. Beberashvili et al. reported that a lower serum UA level was correlated with lower geriatric nutritional risk index scores 11 . We consider serum UA to be a superficial nutritional marker along with serum albumin and creatinine in haemodialysis CKD patients, and that the UA level should be relatively higher in haemodialysis patients. Higher UA levels were associated with better outcomes than lower levels in haemodialysis CKD patients 10, 11 . However, achieving the therapeutic target of a lower UA would be due to the effects of the XORi rather than nutritional deficits. The optimal level of UA in haemodialysis is controversial. In the results of the present study, all UA quintiles showed a strong treatment effect (Fig. 5a ) along with a protective effect for new-onset hypertensive diseases (Fig. 5b) . We suggest that XORi administration in haemodialysis patients with higher UA levels along with those with lower UA levels improved outcomes.
XOR-derived free radicals may cause endothelial dysfunction and vasoconstriction by lowering nitric oxide availability and stimulating the upregulation of the renin-angiotensin system, which plays a pivotal role in inflammatory signalling 25 . Our MSM analysis indicated that XOR inhibition reduced the likelihood of the hypertensive diseases, suggesting that XOR inhibition acts directly on the vascular membrane. Through the activation of ROS, membrane damage, tissue hypoxia and endothelial dysfunction, hyperuricaemia is linked to or even provokes hypertension and coronary artery disease 26 . Our study did not find a reduction in new-onset ischaemic heart disease occurrence, but did find a preventive effect of XORi treatment against hypertensive diseases, which was be associated with stimulated NO production via XOR inhibitor-mediated suppression of oxidative stress 25 (Fig. 5b) .
Gondowin et al. reported that serum XOR activity was inversely related to Vitamin C and the oxidative enzyme xanthine oxidase, and serum XOR activity was increased in haemodialysis CKD patients compared with nondialysis CKD patients 27 . Nevertheless, the serum UA level was reportedly decreased in haemodialysis CKD patients compared with that in nondialysis CKD patients 27 . These findings suggest that the main determinant of oxidative stress production is xanthine oxidase activity, rather than the serum UA level, in both nondialysis and haemodialysis CKD patients. Mervaala et al. previously examined whether XOR produces the ROS, which are involved in the onset of angiotensin II (Ang II)-induced vascular dysfunction in double transgenic rats, and showed that Ang II-induced endothelial dysfunction was indeed associated with increased oxidative stress and vascular XO activity 28 hypertension, with the ameliorating effects of a XORi elicited via its effect on NO synthesis in spontaneously hypertensive rats 29 .
These results from animal studies suggest that, together with progressive purine metabolism, the activation of tissue RAS and CKD progression may be a trigger that transforms XDH to XO in an oxidative-stress inducible form, and thus causes tissue damage. Since haemodialysis with residual renal function might be carried over to RAS activation, it is suggested that one cause of high XO is RAS activation; other causes include uraemia, hypoxia, and chronic inflammation. Additionally, XORi may have the ability to cut off the pathway from XO to tissue damage along with its effect on purine hypermetabolism.
It is expected that the administration of XORi in haemodialysis CKD patients, particularly those with high XO, would improve NO synthesis and exert ameliorating effects on the endothelial dysfunction evoked by oxidative The treatment effect of XORi on CVD events was associated with a HR of 0.92 (95% CI 0.76-1.12) in all quintiles. The treatment effect for hypertensive disease included in the CVD events indicated a significantly preventive effect with a HR of 0.35 (95% CI 0.16-0.75). The HR was 0.91, 0.997, 1.05 and 1.05 in heart failure, ischaemic heart disease, atrial fibrillation (af) and valvular disease, respectively. CVD events other than hypertensive disease, heart failure, ischaemic heart disease, af and vulvar disease, could not be calculated in MSM analysis due to the small number of outcomes. stress and thus prevent tissue damage 30 . The present investigation of haemodialysis patients found that serum UA level was not an independent risk factor for all-cause mortality in the Cox model, but XORi was correlated with mortality, with a minor difference at baseline. It appears that the higher UA group among the haemodialysis CKD patients had a CVD event risk similar to that among patients with hyperuricaemia in the nondialysis population 18, 31 . Nevertheless, the haemodialysis CKD patients with a wide range of serum UA levels were administered XORi in the present study, and the preventive effect on outcomes is likely to be due to the beneficial effect of XOR inhibition, even in the relatively lower UA group.
We presume that the high quintile group was exposed to a high oxidative stress environment along with an insufficient XORi dose in the higher UA group in this cohort ( Table 1) . As described in the study by Gondowin 27 , the serum XOR concentration in the haemodialysis CKD patients was higher than that in nondialysis CKD patients. We also presume that a higher administration rate of XORi in quintiles 4 and 5 (i.e., higher serum UA levels) would have a more favourable effect. In haemodialysis, a large amount of UA is removed, which is why attacks of gout are very rare. However, it is suggested that the underlying high XO status would be at the same level or higher as the hyperuricaemia in patients with CKD 23 . If UA were not removed during haemodialysis, the serum UA would be very high, with an accompanying attack of gout. A high XO should be presumed and XORi prescribed when high XO is suspected. Norman et al. 32 suggested that a 600-mg/day dose of allopurinol should be considered for patients with stable angina; this may be a sufficiently high dose for patients on haemodialysis, because of the accumulation and urinary excretion limit of allopurinol.
In our cohort, patients in the higher quintiles seemed to have an insufficient dose of XORi; however, the effect of XOR inhibition appeared to be sufficient in all quintiles, even in the lower quintiles (Fig. 5a ). Therefore, it is difficult to determine the difference in the efficacy of XOR inhibition between the quintiles in the present study. Further investigation is needed regarding treatment with newer agents such as topiroxostat. The recommendation from the present study is that a similarly high dose of XORi should be administered in the high and low UA level groups in cases of enhanced oxidative stress production due to malnutrition or chronic inflammatory status, as well as cases of severe lower leg arteriosclerosis or aspiration pneumonia. From the results presented here, it is recommended that XORi administration be initiated even when the serum UA concentration is approximately 6.0 mg/dL. In haemodialysis CKD patients, it has been recommended to lower the serum UA level to the same target level as nondialysis CKD patients to exert the anti-inflammatory effect mediated through its XOR inhibition. Concerning this important issue, the present study evaluated the effects of XOR inhibition, rather than the effect of UA lowering, on mortality due to CVD events.
There are several limitations of this study. First, we evaluated only the administration of XORi and not the dosage of each drug. However, the optimal dosage in haemodialysis patients has not been established. Therefore, we evaluated whether patients were prescribed XORi to evaluate the treatment effect in our statistical analysis. Second, we were not able to collect information about the cause of death after censoring. Information on cause of death in regularly visiting patients was immediately recorded in the system, and, after censoring we collected the outcome information as soon as possible. The cause of death was speculated to be the effect on CVD events and that XOR inhibition also influenced the rate of CV-related death. The third limitation was that combinations of drugs were not included in this analysis design; however, these drugs likely influenced serological markers, and, as in other published randomized trials, bias resulting from combinations of drugs could not be excluded. Fourth, we did not collect data on the incidence of XORi adverse events of XORi, but no serious adverse events were identified in the electronic records. Fifth, new-onset CVD events were derived from diagnoses in connection with claims data. However, the diagnosis was linked with a clinical diagnosis. Hypertensive diseases were defined as worsening of existing hypertension or new onset hypertension with the prescription of anti-hypertensive agents. Heart failure was diagnosed as NYHA II and greater according to the International Classification of Diseases, Tenth Edition (ICD-10), in this large sample. Sixth, there was a negative correlation between treatment and the serum UA level in the propensity score analysis for IPTW; however, this analysis was retrospective and the guideline for hyperuricaemia was not clearly defined. This is because recently reported evidence based on our Kaplan Meier curves showed that a higher UA level leads to more favourable outcomes than lower levels. We deduced that this reverse correlation of treatments and serum UA in IPTW creation was the result of adjustment for unusual XORi prescription patterns, such as the lower administration rate in the higher UA group. Table 1 shows a 12.8% rate of XORi prescription in quintile 5 at baseline and a 13.3% rate in the quintile 4 group, whereas rates of 31.6% and 22.8% are evident in quintile 1 and quintile 2, respectively. However, the negative correlation between XORi treatment and UA in the IPTW analysis is reflected in this prescription pattern. Further investigation is needed regarding this adjustment in future studies.
In conclusion, XOR inhibition was estimated in this repeated measured analysis to improve all-cause mortality and CVD events in end-stage renal disease patients on haemodialysis. The true therapeutic goal of treatment with XORi is suggested to be control of XOR activity rather than control of the serum UA level.
Methods
Study Population. The patient population consisted of 4852 haemodialysis patients treated in our group clinics. Cases were excluded based on insufficient demographic data (1088 cases), incomplete diagnosis and comorbidity data (281 cases), no baseline uric acid data (338 cases), incomplete data on BP and HR (627 cases) and lack of information on height (89 cases). Ultimately, this study included 2429 haemodialysis patients who were outpatients treated in 30 haemodialysis clinics in Yokohama Japan, between April 1, 2013 and March 31, 2016 ( Fig. 1 ).
Data Sources. The dialysis information system (STEP II ® ) includes information on the demographic data and outcomes, including information on the cause of death, and the STEPII ® system links to a laboratory data system and prescription data system. The start dates of the diagnosis and comorbidities were derived from the
